Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 58

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 58
---
   -   584,415 Others  7,370   99,447   15,121   45,252 TOTAL OTHER INCOME  52,464   248,417   76,058   855,894                  OPERATING EXPENSES                Sales and marketing  (56,064)  (1,068,531)  (54,116)  (223,699)Research and development  (24,696)  -   (19,673)  - General and administrative  (205,170)  (286,724)  (111,429)  (252,162)Fair value loss on investments in equity securities  -   (119,499)  -   (100,433)Provision for expected credit losses   -   (40,124)  -   (120,469)TOTAL OPERATING EXPENSES  (285,930)  (1,514,878)  (185,218)  (696,763)                 (LOSS)/PROFIT FROM OPERATIONS  (231,063)  (557,349)  (105,104)  808,826                  FINANCE COSTS  (6,637)  (3,101)  (4,596)  (4,433)                 (LOSS)/PROFIT BEFORE TAX  (237,700)  (560,450)  (109,700)  804,393                  Tax expense  -   -   -   (75,652)                 NET (LOSS)/PROFIT ATTRIBUTABLE TO COMMON SHAREHOLDERS $(237,700) $(560,450) $(109,700) $728,741 

 40Table of Contents

Revenue. 

For the current six month period ended June 30, 2025, we had total revenue of $4,397,328, an increase of 0.9% as compared to total revenue of $4,356,415 for the same period in the previous year.

MRNA Scientific contributed $6,534 (0.1%) of the total revenue for the current six month period ended June 30,